These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 16644553)

  • 1. 3D-QSAR study on heterocyclic topoisomerase II inhibitors using CoMSIA.
    Tekiner-Gulbas B; Temiz-Arpaci O; Yildiz I; Aki-Sener E; Yalcin I
    SAR QSAR Environ Res; 2006 Apr; 17(2):121-32. PubMed ID: 16644553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D-QSAR analysis on benzazole derivatives as eukaryotic topoisomerase II inhibitors by using comparative molecular field analysis method.
    Temiz-Arpaci O; Tekiner-Gulbas B; Yildiz I; Aki-Sener E; Yalcin I
    Bioorg Med Chem; 2005 Dec; 13(23):6354-9. PubMed ID: 15993083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3D-QSAR CoMSIA study on 3-azolylmethylindoles as anti-leishmanial agents.
    Giraud F; Loge C; Le Borgne M; Pagniez F; Na YM; Le Pape P
    SAR QSAR Environ Res; 2006 Jun; 17(3):299-309. PubMed ID: 16815769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors.
    Pinar A; Yurdakul P; Yildiz I; Temiz-Arpaci O; Acan NL; Aki-Sener E; Yalcin I
    Biochem Biophys Res Commun; 2004 Apr; 317(2):670-4. PubMed ID: 15063810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
    Puntambekar D; Giridhar R; Yadav MR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
    Doddareddy MR; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
    Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E
    SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues.
    Juvale DC; Kulkarni VV; Deokar HS; Wagh NK; Padhye SB; Kulkarni VM
    Org Biomol Chem; 2006 Aug; 4(15):2858-68. PubMed ID: 16855733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting anti-cancer activity of quinoline derivatives: CoMFA and CoMSIA approach.
    Vaidya A; Jain AK; Kumar P; Kashaw SK; Agrawal RK
    J Enzyme Inhib Med Chem; 2011 Dec; 26(6):854-61. PubMed ID: 21476832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
    Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
    J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
    Patel MR; Talele TT
    Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.
    Lu P; Wei X; Zhang R
    Eur J Med Chem; 2010 Aug; 45(8):3413-9. PubMed ID: 20488589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular docking and 3D-QSAR studies of Yersinia protein tyrosine phosphatase YopH inhibitors.
    Hu X; Stebbins CE
    Bioorg Med Chem; 2005 Feb; 13(4):1101-9. PubMed ID: 15670918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.